Quest Diagnostics' Simplexa Influenza A H1N1 (2009) test receives CE mark

Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that the Simplexa Influenza A H1N1 (2009) test developed by its Focus Diagnostics business has been CE marked and is now available as a test kit for distribution to approximately 35 countries in Europe. Focus Diagnostics is showcasing the test at MEDICA 2009, November 18 to 21, 2009, at the Dusseldorf Fair Trade Centre, Hall 3, Stand D20, Booth 2 (American Pavilion).

"As the influenza A(H1N1) 2009 virus continues to spread across the globe, it is imperative that clinicians have access to reliable tests for quickly and definitively identifying infected patients," said Harald Kessler, M.D., professor and head of the research unit "Molecular Diagnostics", Medical University of Graz, Austria. "The new Simplexa assay may contribute to a fast and reliable option for generating 2009 H1N1 virus test results in molecular laboratories throughout Europe and many other regions. Fast turnaround time can aid in clinical management of patients and allow hospitals to segregate infected patients from other high-risk individuals."

The Focus Diagnostics Simplexa(TM) Influenza A H1N1 (2009) test employs real-time reverse transcription polymerase chain reaction (RT-PCR) to qualitatively detect the 2009 H1N1 flu virus in a patient's nasal or nasopharyngeal specimens. The test targets a region of the hemagglutinin gene of the 2009 H1N1 influenza virus specifically to detect the presence of 2009 H1N1 influenza RNA, thereby differentiating it from seasonal human influenza A viruses. The World Health Organization (WHO), which provides guidance for countries managing the pandemic, states that RT-PCR is the "only rapid diagnostic test for which a positive result is accepted as confirmation" of human infection with the 2009 H1N1 pandemic virus.(1)

The Focus Diagnostics Simplexa(TM) Influenza A H1N1 (2009) test is an outgrowth of an exclusive global distribution agreement between Focus Diagnostics and 3M (NYSE: MMM) under which Focus will develop and offer molecular diagnostic test kits, to be sold under the Simplexa brand name, on the 3M Integrated Cycler. The 3M Integrated Cycler supports real-time polymerase chain reaction (PCR) technology and employs advanced data management software to help laboratories process, store and transfer data quickly and effectively. It can process up to 96 samples per run, and provides results in 30 to 85 minutes, depending on the test's parameters. It has a small laboratory footprint, at approximately 31 centimeters (12 inches) high and 31 centimeters long.

The Simplexa Influenza A H1N1 (2009) test, which was launched in October 2009, is the first offering from the Simplexa product line. Focus Diagnostics plans to launch additional Simplexa test kits on the 3M Integrated Cycler for infectious diseases in 2010, pending required regulatory clearances.

Quest Diagnostics' Focus Diagnostics has a track record of being first to market with new laboratory testing services for emerging infectious diseases. The company introduced a 2009 H1N1 flu test approximately two weeks after the U.S. Department of Health and Human Services declared a pandemic emergency in the U.S. in late April. The U.S. Food and Drug Administration (FDA), the regulatory body that oversees diagnostic testing in the U.S., granted emergency use authorizations to Focus Diagnostics for its first test as well as its new Simplexa test.

"Expanded influenza capability could be critically important as the pandemic virus continues its spread globally," said John G. Hurrell, PhD, vice president and general manager, Focus Diagnostics. "Our Simplexa test affords many hospital, health clinic and reference laboratories the ability to quickly produce results, even when faced with high volumes of testing, using a compact, reliable molecular device."

Source:

Quest Diagnostics Incorporated

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Quest Diagnostics. (2019, June 19). Quest Diagnostics' Simplexa Influenza A H1N1 (2009) test receives CE mark. News-Medical. Retrieved on November 24, 2020 from https://www.news-medical.net/news/20091118/Quest-Diagnostics-Simplexa-Influenza-A-H1N1-(2009)-test-receives-CE-mark.aspx.

  • MLA

    Quest Diagnostics. "Quest Diagnostics' Simplexa Influenza A H1N1 (2009) test receives CE mark". News-Medical. 24 November 2020. <https://www.news-medical.net/news/20091118/Quest-Diagnostics-Simplexa-Influenza-A-H1N1-(2009)-test-receives-CE-mark.aspx>.

  • Chicago

    Quest Diagnostics. "Quest Diagnostics' Simplexa Influenza A H1N1 (2009) test receives CE mark". News-Medical. https://www.news-medical.net/news/20091118/Quest-Diagnostics-Simplexa-Influenza-A-H1N1-(2009)-test-receives-CE-mark.aspx. (accessed November 24, 2020).

  • Harvard

    Quest Diagnostics. 2019. Quest Diagnostics' Simplexa Influenza A H1N1 (2009) test receives CE mark. News-Medical, viewed 24 November 2020, https://www.news-medical.net/news/20091118/Quest-Diagnostics-Simplexa-Influenza-A-H1N1-(2009)-test-receives-CE-mark.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
New study reveals high percentages of unsafe blood lead levels among U.S. children